What Other Infections Does Vivotif (Ty21a) Prevent?
The oral Ty21a typhoid vaccine (Vivotif) provides moderate protection against Salmonella Paratyphi B infection (approximately 49% efficacy), but does NOT protect against Salmonella Paratyphi A infection. 1, 2
Evidence from Field Trials
The most definitive evidence comes from randomized controlled field trials in Santiago, Chile:
Paratyphoid B Protection: When data from two large Chilean field trials were pooled (involving over 192,000 school-aged children), Ty21a demonstrated 49% efficacy (95% CI: 8%-73%) against paratyphoid B fever over 3 years of follow-up 2. Individual trials showed trends of 56% efficacy in one trial and 42% in another, though neither reached statistical significance alone 2.
No Paratyphoid A Protection: The guidelines explicitly state that paratyphoid A vaccine effectiveness has never been established, and field trials demonstrated that paratyphoid antigens are not effective 1. This is further supported by immunological studies showing significantly lower cross-reactive antibody responses to S. Paratyphi A compared to S. Paratyphi B 3.
Immunological Basis for Cross-Protection
The mechanism underlying this differential protection relates to shared surface antigens:
Why Paratyphi B: S. Paratyphi B shares both O-9 and O-12 antigens with S. Typhi, resulting in robust cross-reactive immune responses 4. Studies show similar magnitudes of multifunctional CD8+ T-cell responses to both S. Typhi and S. Paratyphi B following Ty21a immunization 5.
Why NOT Paratyphi A: Despite demonstrable cross-reactive humoral and cellular immune responses to S. Paratyphi A antigens, these responses are significantly weaker and cannot explain the lack of field efficacy 3. The cross-reactive antibody response to S. Paratyphi A LPS is significantly lower than to S. Paratyphi B 3.
Potential Cross-Protection Against Non-Typhoidal Salmonella
Emerging research suggests Ty21a may provide cross-protection against certain non-typhoidal Salmonella (NTS) strains that share O-antigens with S. Typhi 4:
- Strong gut-directed cross-reactive responses against S. Enteritidis (shares O-9,12 antigens)
- Weaker responses against S. Typhimurium (shares O-12 antigen only)
- No responses against NTS strains without typhoidal O-antigens
However, this remains theoretical - no field efficacy data exist to confirm actual protection against NTS infections in real-world settings 4.
Critical Clinical Caveat
Ty21a is a monovalent vaccine containing only S. Typhi antigens 1. The guidelines explicitly recommend against using combined typhoid-paratyphoid vaccines (TAB vaccines) because:
- They increase adverse reaction rates
- The paratyphoid components are ineffective
- Only monovalent S. Typhi preparations should be used 1
Bottom Line
For travelers to endemic areas, Ty21a provides documented protection against both typhoid fever (50% efficacy over 3 years) and paratyphoid B fever (49% efficacy), but offers no protection against paratyphoid A - an increasingly important pathogen in south-central and southeast Asia 6. This limitation is driving development of bivalent S. Typhi/S. Paratyphi A vaccines 5.